Published in J Clin Oncol on March 10, 2007
Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol (2012) 1.33
Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol (2010) 1.23
Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol (2008) 1.18
Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol (2010) 1.11
Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas. Clin Orthop Relat Res (2013) 0.89
Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol (2011) 0.83
Early complications of high-dose-rate brachytherapy in soft tissue sarcoma: a comparison with traditional external-beam radiotherapy. Clin Orthop Relat Res (2012) 0.82
Intraoperative pelvic brachytherapy for treatment of locally advanced or recurrent colorectal cancer. Tech Coloproctol (2012) 0.81
Emergency surgery in patients who have undergone recent radiotherapy is associated with increased complications and mortality: review of 536 patients. World J Surg (2012) 0.80
ACR Appropriateness Criteria®-Recurrent Rectal Cancer. Gastrointest Cancer Res (2012) 0.79
Influence of intraoperative radiotherapy (IORT) on perioperative outcome after surgical resection of rectal cancer. World J Surg (2014) 0.79
Intraoperative radiation therapy for advanced cervical metastasis: a single institution experience. Radiat Oncol (2011) 0.78
Minimally invasive surgery using intraoperative electron-beam radiotherapy for the treatment of soft tissue sarcoma of the extremities with tendon involvement. World J Surg Oncol (2016) 0.78
Efficacy of intraoperative radiotherapy targeted to the abdominal lymph node area in patients with esophageal carcinoma. J Radiat Res (2012) 0.75
High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program. J Contemp Brachytherapy (2014) 0.75
Intraoperative radiotherapy with low energy photons in recurrent colorectal cancer: a single centre retrospective study. Contemp Oncol (Pozn) (2016) 0.75
Intraoperative radiotherapy for locally advanced rectal cancer. J Korean Soc Coloproctol (2010) 0.75
Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven. J Gastrointest Oncol (2016) 0.75
Safety, effectiveness and economic evaluation of intra-operative radiation therapy: a systematic review. Med J Islam Repub Iran (2015) 0.75
Intraoperative radiation therapy (IORT) in head and neck cancer: A systematic review. Medicine (Baltimore) (2016) 0.75
High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins. Brachytherapy (2016) 0.75
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg (2011) 1.82
Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle (2008) 1.76
The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
Locally advanced pancreatic cancer. J Clin Oncol (2005) 1.55
Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol (2004) 1.52
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park) (2010) 1.48
Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol (2006) 1.47
Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol (2008) 1.36
Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg (2003) 1.30
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg (2014) 1.26
Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med (2005) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist (2010) 1.23
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15
Thirty years of rectal cancer research: a brief history. Oncology (Williston Park) (2008) 1.15
Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer (2009) 1.14
Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys (2010) 1.12
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist (2010) 1.11
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res (2008) 1.11
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther (2010) 1.08
Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 1.08
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol (2011) 1.07
Oncolytic polio virotherapy of cancer. Cancer (2014) 1.05
Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood (2007) 1.05
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03
The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. J Surg Oncol (2006) 1.02
Workforce projections for hepato-pancreato-biliary surgery. J Am Coll Surg (2008) 1.02
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer (2009) 1.01
Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol (2009) 1.01
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol (2012) 1.00
Extended resection for pancreatic adenocarcinoma. Oncologist (2007) 0.99
Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol (2006) 0.99
Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J Am Geriatr Soc (2011) 0.96
Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol (2006) 0.95
The role of local excision in invasive adenocarcinoma of the ampulla of Vater. J Gastrointest Oncol (2013) 0.94
Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am (2004) 0.94
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol (2011) 0.94
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.93
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res (2006) 0.93
Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg (2005) 0.93
Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. Ann Surg Oncol (2014) 0.93
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol (2007) 0.92
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res (2004) 0.92
Incidence of benign disease in patients that underwent resection for presumed pancreatic cancer diagnosed by endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). J Gastrointest Surg (2010) 0.92
Soft tissue sarcoma. J Natl Compr Canc Netw (2007) 0.91
Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol (2004) 0.91
Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am (2011) 0.89
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther (2010) 0.89
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol (2011) 0.89
Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg (2009) 0.89
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res (2005) 0.89
Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol (2013) 0.89
Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res (2002) 0.89
CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. J Invest Dermatol (2012) 0.88
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer (2004) 0.88
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest (2013) 0.87
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg (2004) 0.87
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys (2007) 0.87
Enhancing melanoma treatment with resveratrol. J Surg Res (2010) 0.87
Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg (2002) 0.86
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res (2012) 0.85
CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Surgery (2003) 0.85
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Pancreaticoduodenectomy: frequency and outcome of post-operative imaging-guided percutaneous drainage. Abdom Imaging (2009) 0.84
Emerging role of intensity-modulated radiation therapy in anorectal cancer. Expert Rev Anticancer Ther (2008) 0.84
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther (2006) 0.84
Radiation therapy in stage II and III rectal cancer. Clin Cancer Res (2007) 0.84
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One (2013) 0.83
Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. Blood (2012) 0.83
Feeding jejunostomy tube placement in patients undergoing pancreaticoduodenectomy: an ongoing dilemma. J Gastrointest Surg (2014) 0.83
A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg (2012) 0.83
Vascular surgery collaboration during pancreaticoduodenectomy with vascular reconstruction. Ann Vasc Surg (2012) 0.83